Arsenal Biosciences

Executive Summary

Arsenal Biosciences is a clinical-stage, programmable cell therapy company dedicated to overcoming the challenges of solid tumors with engineered T cell therapies. Founded in 2019 and headquartered in South San Francisco, the company leverages a computationally driven integrated platform to design medicines with multiple coordinated functions, aiming to enhance activity and safety. Its mission is to defeat cancer through advanced cell therapies that address the complex biology of solid tumors, distinguishing it from traditional CAR-T approaches that have succeeded mainly in hematologic malignancies. The company's lead program is in Phase 1 development, targeting solid tumor antigens with a novel synthetic biology circuit designed to improve tumor infiltration, persistence, and control of off-tumor toxicity. Arsenal has built a proprietary toolkit that combines genetic engineering, computational modeling, and high-throughput screening to create T cells with programmable logic. The company is advancing its pipeline through internal research and strategic collaborations. While still in early clinical stages, it has shown promising preclinical data and is expected to release initial clinical data from its lead program in the coming quarters. The company's approach has attracted significant investor interest due to its potential to address large unmet needs in solid tumors. Key upcoming catalysts include the readout of Phase 1 safety and efficacy data, which will be critical for validating the platform and determining the path to later-stage trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for lead candidate60% success
• Q2 2027IND submission for second program70% success
• H2 2026Potential partnership or licensing deal50% success